Treace Medical Concepts Slides After Cut to Full-Year Revenue Outlook

Dow Jones

2025/11/08

By Terell Wright

Shares of Treace Medical Concepts fell after the medical-technology company lowered its full-year revenue outlook, citing softening customer demand for elective bunion surgeries.

Shares fell 34%, to $4.10, midday Friday, after touching a new 52-week low earlier in the day. Year-to-date, shares are down nearly 45%.

The company on Thursday cut its full-year revenue guidance to a range of $211 million to $213 million, from a prior range of $224 million to $230 million. Analysts expected $216.9 million, according to FactSet.

Chief Executive John Treace said the company lowered its outlook because shifting surgeon and patient preferences favor minimally invasive solutions, and economic conditions are causing patients to defer elective bunion surgery.

The Ponte Vedra Beach, Fla., company's third-quarter loss widened to $16.3 million, or 26 cents a share, from $15.4 million, or 25 cents a share, a year earlier. Analysts expected a loss of 28 cents a share.

Revenue rose 11%, to $50.2 million, ahead of Wall Street's estimate for $49.8 million.

Write to Terell Wright at terell.wright@wsj.com

(END) Dow Jones Newswires

November 07, 2025 15:05 ET (20:05 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2581836445"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581836445\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581836445?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-08 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581836445","market":"nz","top_or_hot":-1,"title":"Treace Medical Concepts Slides After Cut to Full-Year Revenue Outlook","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Terell Wright \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Treace Medical Concepts fell after the medical-technology company lowered its full-year revenue outlook, citing softening customer demand for elective bunion surgeries. \n</p>\n<p>\n  Shares fell 34%, to $4.10, midday Friday, after touching a new 52-week low earlier in the day. Year-to-date, shares are down nearly 45%. \n</p>\n<p>\n  The company on Thursday cut its full-year revenue guidance to a range of $211 million to $213 million, from a prior range of $224 million to $230 million. Analysts expected $216.9 million, according to FactSet. \n</p>\n<p>\n  Chief Executive John Treace said the company lowered its outlook because shifting surgeon and patient preferences favor minimally invasive solutions, and economic conditions are causing patients to defer elective bunion surgery. \n</p>\n<p>\n  The Ponte Vedra Beach, Fla., company's third-quarter loss widened to $16.3 million, or 26 cents a share, from $15.4 million, or 25 cents a share, a year earlier. Analysts expected a loss of 28 cents a share. \n</p>\n<p>\n  Revenue rose 11%, to $50.2 million, ahead of Wall Street's estimate for $49.8 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Terell Wright at terell.wright@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 07, 2025 15:05 ET (20:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Treace Medical Concepts Slides After Cut to Full-Year Revenue Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTreace Medical Concepts Slides After Cut to Full-Year Revenue Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-08 04:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Terell Wright \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Treace Medical Concepts fell after the medical-technology company lowered its full-year revenue outlook, citing softening customer demand for elective bunion surgeries. \n</p>\n<p>\n  Shares fell 34%, to $4.10, midday Friday, after touching a new 52-week low earlier in the day. Year-to-date, shares are down nearly 45%. \n</p>\n<p>\n  The company on Thursday cut its full-year revenue guidance to a range of $211 million to $213 million, from a prior range of $224 million to $230 million. Analysts expected $216.9 million, according to FactSet. \n</p>\n<p>\n  Chief Executive John Treace said the company lowered its outlook because shifting surgeon and patient preferences favor minimally invasive solutions, and economic conditions are causing patients to defer elective bunion surgery. \n</p>\n<p>\n  The Ponte Vedra Beach, Fla., company's third-quarter loss widened to $16.3 million, or 26 cents a share, from $15.4 million, or 25 cents a share, a year earlier. Analysts expected a loss of 28 cents a share. \n</p>\n<p>\n  Revenue rose 11%, to $50.2 million, ahead of Wall Street's estimate for $49.8 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Terell Wright at terell.wright@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 07, 2025 15:05 ET (20:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TMCI","symbol_name":"Treace Medical Concepts, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2581836445","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581836445","pubTimestamp":1762545900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Treace Medical Concepts fell after the medical-technology company lowered its full-year revenue outlook, citing softening customer demand for elective bunion surgeries.Shares fell 34%, to $4.10, midday Friday, after touching a new 52-week low earlier in the day. Year-to-date, shares are down nearly 45%.The company on Thursday cut its full-year revenue guidance to a range of $211 million to $213 million, from a prior range of $224 million to $230 million. Analysts expected $216.9 million, according to FactSet.Chief Executive John Treace said the company lowered its outlook because shifting surgeon and patient preferences favor minimally invasive solutions, and economic conditions are causing patients to defer elective bunion surgery.The Ponte Vedra Beach, Fla., company's third-quarter loss widened to $16.3 million, or 26 cents a share, from $15.4 million, or 25 cents a share, a year earlier. Analysts expected a loss of 28 cents a share.Revenue rose 11%, to $50.2 million, ahead","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TMCI":"Treace Medical Concepts, Inc."},"translate_title":"Treace Medical Concepts下调全年收入预期后股价下滑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMCI":1.5},"content_text":"By Terell Wright \n\n\n \n\n\n  Shares of Treace Medical Concepts fell after the medical-technology company lowered its full-year revenue outlook, citing softening customer demand for elective bunion surgeries. \n\n\n  Shares fell 34%, to $4.10, midday Friday, after touching a new 52-week low earlier in the day. Year-to-date, shares are down nearly 45%. \n\n\n  The company on Thursday cut its full-year revenue guidance to a range of $211 million to $213 million, from a prior range of $224 million to $230 million. Analysts expected $216.9 million, according to FactSet. \n\n\n  Chief Executive John Treace said the company lowered its outlook because shifting surgeon and patient preferences favor minimally invasive solutions, and economic conditions are causing patients to defer elective bunion surgery. \n\n\n  The Ponte Vedra Beach, Fla., company's third-quarter loss widened to $16.3 million, or 26 cents a share, from $15.4 million, or 25 cents a share, a year earlier. Analysts expected a loss of 28 cents a share. \n\n\n  Revenue rose 11%, to $50.2 million, ahead of Wall Street's estimate for $49.8 million. \n\n\n \n\n\n  Write to Terell Wright at terell.wright@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 15:05 ET (20:05 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}